Company profile
APOLLOMICS INC.
NASDAQ:APLMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VEBRELTINIB | phase1 | — | 1 | unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05367388 | phase1 | unknown | 2022-05-20 | 2022-11-01 | Apollomics Inc. | A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants |
| NCT03175224 | phase2 | recruiting | 2017-09-27 | 2026-03-30 | Apollomics Inc. | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors |
| NCT05055518 | phase1 | suspended | 2021-08-02 | 2028-10-31 | Apollomics Inc. | APL-102 Capsule in Patients With Advanced Solid Tumors |
| NCT04839341 | phase1 | completed | 2021-02-24 | 2024-06-28 | Apollomics Inc. | Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients |
| NCT05054543 | phase3 | terminated | 2021-11-17 | 2024-08-22 | Apollomics Inc. | Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML |
FDA applications (0)
No records yet.